Biography

Dr. Imre Noth received his Bachelor of Arts from the University of Pennsylvania. He then went on to a Masters of Science in Human Physiology at Georgetown University and received his M.D. the University of Arizona College of Medicine. He completed a residency in Internal Medicine at the University of California at Davis Medical Center in Sacramento, CA. He then pursued a Pulmonary and Critical Care Fellowship at the University of Chicago, where upon completion in 1999 he joined the faculty. He rose to the rank of Professor of Medicine at the University of Chicago in 2012. Dr. Noth is a premiere translational researcher in Interstitial Lung Disease. Over the last decade and a half, he has concentrated his efforts on interstitial lung diseases with a special emphasis on idiopathic pulmonary fibrosis (IPF). This has allowed him to focus on the unique needs of this patient population. Dr. Noth has participated--and continues to participate--as principal investigator in numerous clinical trials funded by industry and the NHLBI/NIH that focus predominantly on IPF. As the principal investigator for a U10 award, he was a member of the National Institutes of Health sponsored IPF clinical research network and served on the executive committee for the IPFnet. He has also collaborated on other RO1 and UO1 awards. His recent research includes studying the relationship between genetics, genomics and outcomes in IPF, as well as in the conduct of novel clinical trials in IPF. His work in genetics resulted in a RC1 “Challenge” grant ward in Genetics. He has authored 67 peer-reviewed manuscripts and has mentored numerous trainees. In addition to authoring several book chapters on critical care medicine, Dr. Noth is a reviewer for the American Journal of Respiratory and Critical Care Medicine and the Journal of Respiratory Diseases. He also sits on the editorial board for Chest. Through the ILD program, he hopes to continue to conduct research that will allow a better understanding of the natural history of interstitial lung diseases and develop better approaches to therapy.

Read More